Payment overview · 2025
General Payments
$253.03
12 reported records · 6 companies
Healthcare provider profile · identity verified
Bhavya Kumar, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ELMHURST, IL · NPI 1578977922
Verified facts
What the public records show
CMS Open Payments records show Bhavya Kumar, MD received $253.03 in general payments during 2025 across 12 reported records.
Exact Sciences Corporation accounted for 42.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ingrezza, Ozempic.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Jardiance by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Ingrezza by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 437 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $106.41 | 42.0% | 5 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $35.89 | 14.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.50 | 13.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $31.02 | 12.3% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $23.16 | 9.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.05 | 8.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $253.03 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $55.72 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $35.89 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $33.67 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $31.02 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $31.02 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $31.02 | 1 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $31.02 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $23.16 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.05 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.04 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
437 | 45 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 437 | 45 |
| Atorvastatin Calcium | Atorvastatin Calcium | 343 | 78 |
| Levothyroxine Sodium | Levothyroxine Sodium | 211 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 202 | 50 |
| Furosemide | Furosemide | 189 | 53 |
| Escitalopram Oxalate | Escitalopram Oxalate | 188 | 38 |
| Potassium Chloride | Potassium Chloride | 188 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 182 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 171 | 40 |
| Gabapentin | Gabapentin | 161 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 145 | 34 |
| Omeprazole | Omeprazole | 141 | 31 |
| Mirtazapine | Mirtazapine | 136 | 26 |
| Lisinopril | Lisinopril | 135 | 33 |
| Donepezil Hcl | Donepezil Hcl | 125 | 27 |
| Sertraline Hcl | Sertraline Hcl | 104 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 93 | 21 |
| Memantine Hcl | Memantine Hcl | 92 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 91 | 29 |
| Losartan Potassium | Losartan Potassium | 82 | 26 |
| Allopurinol | Allopurinol | 77 | 11 |
| Carvedilol | Carvedilol | 76 | 25 |
| Metformin Hcl | Metformin Hcl | 75 | 18 |
| Famotidine | Famotidine | 72 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 65 | suppressed |
| Latanoprost | Latanoprost | 65 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 64 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 63 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 12 |
| Simvastatin | Simvastatin | 60 | 15 |
| Levetiracetam | Levetiracetam | 59 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 56 | 18 |
| Gemtesa | Vibegron | 56 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 52 | suppressed |
| Enulose | Lactulose | 51 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 51 | 18 |
| Trazodone Hcl | Trazodone Hcl | 51 | 12 |
| Ingrezza | Valbenazine Tosylate | 49 | suppressed |
| Bumetanide | Bumetanide | 48 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 47 | suppressed |
| Xarelto | Rivaroxaban | 46 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 45 | 11 |
| Lactulose | Lactulose | 45 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 44 | 15 |
| Januvia | Sitagliptin Phosphate | 43 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 42 | 14 |
| Warfarin Sodium | Warfarin Sodium | 42 | suppressed |
| Ezetimibe | Ezetimibe | 41 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 40 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 38 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 36 | suppressed |
| Jardiance | Empagliflozin | 36 | suppressed |
| Cephalexin | Cephalexin | 35 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 34 | suppressed |
| Aripiprazole | Aripiprazole | 31 | suppressed |
| Lacosamide | Lacosamide | 31 | suppressed |
| Sucralfate | Sucralfate | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 22 |
| Sps | Sodium Polystyrene Sulfon/Sorb | 29 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 29 | suppressed |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 27 | 17 |
| Spironolactone | Spironolactone | 26 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 25 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 25 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 25 | 12 |
| Prednisone | Prednisone | 22 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | 12 |
| Diltiazem 24hr Er | Diltiazem Hcl | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 17 |
| Sulfasalazine | Sulfasalazine | 21 | suppressed |
| Alprazolam | Alprazolam | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Xifaxan | Rifaximin | 20 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 19 | 11 |
| Enoxaparin Sodium | Enoxaparin Sodium | 18 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Loperamide | Loperamide Hcl | 17 | 11 |
| Pregabalin | Pregabalin | 17 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 17 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Nystatin | Nystatin | 16 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Daptomycin | Daptomycin | 15 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Levemir | Insulin Detemir | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 12 | 12 |
| Clonidine | Clonidine | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Ozempic | Semaglutide | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Permethrin | Permethrin | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Epogen | Epoetin Alfa | 11 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Leflunomide | Leflunomide | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $253.03 · 12 records | Exact Sciences Corporation | AUSTEDO XR, COMIRNATY, Cologuard Collection Kit, INGREZZA, Ozempic, PENBRAYA, PREVNAR 20, Rybelsus, TRUMENBA, The Cologuard Plus Collection Kit, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ingrezza play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error